Thank you for the submission of your manuscript to EMBO Molecular Medicine. We have now received comments from the Reviewers whom we asked to evaluate your manuscript.
(CCR1) drastically reduces accumulation of IMCs and tumor burden in the V600EBRAF mice.
2) Ex vivo experiments using primary cells showed that IMCs promote proliferation and cause transcriptional changes indicating EMT consistent with the phenotypes of tumor cells co-cultured with IMCs.
3) However, a different in vivo experiment, in which the compound V600EBRAF/NPC2hypomorphic mice were analyzed, the dramatic increase of IMCs in the stroma did not increase the tumor burden. Based on this observation, the authors concluded that the IMCs "are required for maintenance of early-stage lung tumors".
4)
Additional ex vivo experiments demonstrated that NPC2 secreted from tumor cells acts on the IMCs in a paracrine manner to suppress release of CCL6, which would mediate recruitment of the IMCs to the developing premalignant tumor cells (see 1).
Overall, the study addresses very important questions and suggested a population of stroma cells that may play an important role in BRAF-driven tumor progression. Importantly, the study also found novel roles of CCR1 and NPC2 signaling in regulating the tumor stroma that may influence lung cancer progression. These findings would potentially have significant impacts on developing chemoprevention strategies.
However, a major concern about this study is that it appears to lack a conclusion at least regarding a potential role of IMCs. The conclusions from multiple experiments do not coherently lead to one larger conclusion but rather seem conflicting. It appears that the findings of 1) and 2) are somewhat contradictory to 3) and 4) as far as the role of IMCs is concerned: 1) and 2) suggest an oncogenic role of IMCs while 3) and 4) the opposite. Perhaps, the term "maintenance" used several times in the text to describe the role of IMCs is vague and needs to be better defined.
Minor points are also related to some of the authors' descriptions and conclusions. a) Tumor burden is usually presented as the ratio of total tumor area to total lung area and the number of individual tumors in a given section (Fig. 5 and Fig. 7) . Counting the number of AT2 cells may be less accurate because that count also include wild type AT2 cells, a majority of lung epithelial cells. Please mention briefly in the figure caption why the row of HE stainings was demonstrated along with te lung sample from AdCre+ mice similar to the manuscript text. This will promote the understanding of the figure. There is no mention of the number of tested animals/samples for the each age point used for Ki67 detection and analysis, which is also required to evaluate the data robustness. Please provide the appropriate numbers. Fig. 1C . The data display will be significantly enhanced when the Mac2 staining will be demonstrated on the section adjacent to the HE one, also showing both magnifications, which were used for the HE. In this way the morphological characteristics of the cells mentioned in the manuscript text can be compared to and supported by the Mac 2 staining. Figure S1 . Fig. 1A . A sentence explaining the purpose of the cell isolation would significantly add to the readability. Fig. S1B . It makes more sense to display similar magnification (-s) of the phase-contrast micrographs for the different cell isolates. When it is not quite representative, it might be helpful to include 2 magnifications for each cell type. Generally is quite advantageous to follow the story briefly by the figure captions, which also helps the readership to understand the authors' ideas. Please include very brief description of why you placed the giemsa cell stain also on the figure 2A caption. The same for Fig 2C, very brief mentioning for the purpose of the stain, as for Fig. 2D and 2E. Fig. 2D . Would be really helpful to display the same cells for phase-contrast and giemsa stain, which is I hope not restrictively hard to achieve, but significantly enhance the convincing power of the images. Please also indicate, "phase-contrast" as you indicated giemsa on appropriate images to perform a uniform and easy readable figure. Figure 4 A and B. The figure caption seriously needs better explanation why these pictures are displayed, however brief. Besides, I cannot understand how this blot supports the claim in the manuscript text. To verify against the medium (or what does DMEM stays for other than Dulbecco's Modified Eagle's Medium?) is not the convincing way, since there should be a control with other cell type. Besides, Fig. 4A contains some protein load in the left lane, which is strange and was absolutely not explained anywhere. The experiment for the figure 4 has to be performed with appropriate controls, appropriately displayed and supported by representative loading controls, or completely excluded from this manuscript. The study of Kamata et al addresses interesting and relevant topics on the mechanism of activation of macrophage related cell in tumor microenvironment. The study contains several novel observations, including the response of macrophages-like to the cholesterol-binding protein NPC2.
However the study contains several experimental deficiencies, especially in the data dealing with intracellular trafficking mechanisms induced by NPC2 Major comments 1. Figure 8 B. The signal for LAMP2 staining for lysosomes is too strong , the image is overexposed. The lysosomes, if stained properly, represent very clear discrete structures. The Filipin staining is also overexposed. Therefore the overlap in two signals can be an artefact, and least in part, as well as the quantification of such images. Images with better resolution and improved image acquisition have to be provided. It is also recommended to use not only LAMP2, that is frequently conserved as maker for late endosomes, by also LAMP1. Moreover, markers for other intracellular structures have to be used in parallel to prove the specify of co-localization (EEA1, TGN, Golgi) 2. Figure 8C . The authors write on the page 15, that treatment of IMC by purified bNPC facilitates cholesterol trafficking from late endosomes/lysosomes to the cytosol. However, this is insufficiently documented. The image 8C demonstrates rather reduced total intracellular amount of cholesterol after bNPC treatment. The trafficking was not analyzed here and not demonstrated. The authors have to investigate the trafficking in details, or remove such over-interpretation.
3. The analysis of the mechanism of NPC2-mediated changes in CCL6 release also contains several deficiencies and overestimations. First, Real-time PCR analysis has to be performed to examine the effect of NPC2 on the level of CCL6 transcription. Secondly the image 9D rather demonstrates decreased total level of CCL6, but not its redistribution to lysosomes in response to NPC2. By looking at morphology of CCL6-positive structures it can be assumed that it is Golgi or trans-Golgi network, and CCL6 is localized in the biosynthetic pathway. Lamp2 positive vesicles are localized close to CCL6-positve structure, but this is not real co-localization in the same vesicles. Therefore, making the conclusion about the effect of NPC2 of CCL6 translocation to lysosomes is not justified.
Moreover, targeting of newly synthesized protein to lysosomes is a very specific process, based on the interaction with Mannose-6-phospahe receptors. This process is also very specific for the lisosomal enzymes, and was never shown for cytokines. Proteins , that are transported from TGN to lysosomes are resistant to lysosomal degradation, and can be activated in lysosomes or to be released via lysosomal secretion. If proteins are delivered for the the degradation in lysosomes, that goes by the endosomal pathway. Newly synthesized protein can be rather degraded by proteosomal pathway. Using of Bafilomycin A1 for abrogation of lysosomal function is also insufficiently specific, since Bafilomycin has an effect also on other membrane compartments and can also affect exocytosis in different cell types. The effect of Bafilomycin A1 on the accumulation of CCL6 in intracellular vesicles, including lysosomes, has to be verify also by IF/confocal microscopy Therefore, the conclusion about the of NPC2-mediated mechanism affecting release of CCL6 are insufficiently justified by the experiments.
4.In the abstract is written "Studies on isolated cells ex vivo confirm that NPC2 is secreted from tumour cells and is taken up by IMCs wherein it suppresses secretion of the CCR1 ligand CC chemokine 6 (CCL6)" However, it is not shown in the submission that NPC2 is taken up by IMCs. I was unable to find any data showing the uptake of NPC2 by IMCs. This is very important issue, since it can be that NPC2 only stimulates IMCs by interaction with some surface receptors by induction of signaling and transcriptional events, and does not affect intracellular trafficking events directly. This might also explained the fact that CCL6 levels are decreased in response to NPC2 (has to be checked by RT-PCR, as suggested above).
We thank all of the reviewers for the insightful comments and are pleased to see that all three reviewers agree that this is an interesting and powerful study with a number of novel findings. Each of the reviewers raises a number of recommendations to improve the manuscript and we hope we have done this in the revised version. Our specific comments to the reviewers' recommendations are indicated below.
Referee #1 (Remarks):
The goal of this study is to understand the role of the tumor microenvironment in early cancer progression. Particularly, the authors focus on interactions between tumor and stroma during pre--cancerous development using the oncogenic BRAF (V600EBRAF)--driven model of lung adenocarcinoma, in which pre--cancerous progression of mutant cells can be identified. The major findings of the study are as follows:
1) The authors found a population of macrophage--lineage cells (named IMCs) in the stroma of premalignant tumor, which appears to be immature based on surface marker analysis but expresses several factors, including CC chemokines (e.g. CCL6). Blockade of CC chemokine receptor 1 (CCR1) drastically reduces accumulation of IMCs and tumor burden in the V600EBRAF mice.
2) Ex vivo experiments using primary cells showed that IMCs promote proliferation and cause transcriptional changes indicating EMT consistent with the phenotypes of tumor cells co--cultured with IMCs.
3) However, a different in vivo experiment, in which the compound V600EBRAF/NPC2hypomorphic mice were analyzed, the dramatic increase of IMCs in the stroma did not increase the tumor burden. Based on this observation, the authors concluded that the IMCs "are required for maintenance of early--stage lung tumors". 4) Additional ex vivo experiments demonstrated that NPC2 secreted from tumor cells acts on the IMCs in a paracrine manner to suppress release of CCL6, which would mediate recruitment of the IMCs to the developing premalignant tumor cells (see 1). Overall, the study addresses very important questions and suggested a population of stroma cells that may play an important role in BRAF--driven tumor progression. Importantly, the study also found novel roles of CCR1 and NPC2 signaling in regulating the tumor stroma that may influence lung cancer progression. These findings would potentially have significant impacts on developing chemoprevention strategies. However, a major concern about this study is that it appears to lack a conclusion at least regarding a potential role of IMCs. The conclusions from multiple experiments do not coherently lead to one larger conclusion but rather seem conflicting. It appears that the findings of 1) and 2) are somewhat contradictory to 3) and 4) as far as the role of IMCs is concerned: 1) and 2) suggest an oncogenic role of IMCs while 3) and 4) the opposite. Perhaps, the term "maintenance" used several times in the text to describe the role of IMCs is vague and needs to be better defined.
Ans. We take on board the reviewer's comment here. We agree that Point 3 seems to be somewhat inconsistent with Points 1 and 2. The main issue here, we believe, relates to the level of amplification of IMCs in the Npc2 mutant mice, which is ~2--6 fold (Fig.  6C ). While in theory this level of amplification may be expected to give rise to enhanced EMT and growth of AT2 cells in the Npc2 mutant mice, in reality there was only a trend towards increased AT2 cells (Fig. 6G) , and there was no evidence for enhanced EMT or metastasis. However, we believe these data do not contradict the overall conclusion that IMCs are protumourigenic. Rather they can be explained by the fact that this level of amplification of IMCs is not sufficient to give a dramatic in vivo response and/or the tumour response and IMC quantity do not show a linear correlation in vivo. Actually, IMC accumulation is observed at the senescent stage even in Npc2 +/+ BVE and Braf V600E /AdCre lungs (Fig 1,4 & 6) , and this level of IMC accumulation could be sufficient for near--maximal tumour responses. We believe that abrogation of IMCs by the CCR1 inhibitor provides clear evidence for pro--tumourigenic/tumour--supportive functions of IMCs, and our conclusion that the IMCs "are required for maintenance of early--stage lung tumors" is based on our data from in vivo CCR1 inhibition, rather than those from analysis of Npc2 +/hypo mice. We have removed the last sentence in the paragraph entitled as "NPC2 restrains IMC accumulation" in our results section to avoid any confusion, and included a sentence in the revised discussion to address this point.
Our view is that Point 4 raised by the reviewer does not conflict with the conclusion that IMCs are protumourigenic. Rather, this is a different point entirely, relating to the fact that AT2 cells produce a factor (NPC2) that modulates IMC recruitment to the microenvironment. Minor points are also related to some of the authors' descriptions and conclusions.
a) Tumor burden is usually presented as the ratio of total tumor area to total lung area and the number of individual tumors in a given section (Fig. 5 and Fig. 7). Counting the number of AT2 cells may be less accurate because that count also include wild type AT2 cells, a majority of lung epithelial cells.
Ans. We chose flow cytometry to quantify tumour burden for the following reasons:
(1) As this reviewer points out, tumour area quantification using tissue sections is the most common method to measure tumour burden in mouse models. However, one lung section (5µm thickness) represents only a small portion of total lung volume, and it is unclear if tumour area quantification in 2D--sections accurately reflects 3D--tumour volumes. (2) In our initial attempts to quantify tumour burden using H&E sections, we actually found high variability among different sections from the same lung tissue, suggesting potential risks of selection bias in tumour burden quantification on 2D--sections. This prompted us to develop more reliable and consistent methods. In contrast, contribution of normal AT2 cells in CCR1 inhibitor--treated mice could be much higher (16 -- 33%), since total SPC+ cell numbers in these mice were decreased to 1.0 ~ 2.0 x 10 6 /lobe. Importantly, even though SPC+ cell numbers in these mice could be overestimated by inclusion of normal AT2 cells, they were still much lower than those in vehicle--treated mice (Fig  4F) . Reduction of SPC+ cells by CCR1 inhibition might be more robust if evaluated by tumour--specific quantification methods. At least, the potential error by flow cytometry--based quantification in CCR1 inhibitor--treated mice does not alter our conclusion.
Nevertheless, we quantified %tumour area by the method this reviewer suggested, because it is important to confirm tumour burden by two different methods. We calculated %tumour area in right lobe sections from the mice used in Fig 4F and 6G and the data are presented in the expanded view section.
b) Fig. 1 does not have the legend for B.
Ans. We apologize for this mistake. The legend is now corrected.
c) Oncogene--induced senescence (OIS) is a key phenomenon during early tumor progression.
The authors need to determine senescence phenotype using several standard markers, other than 'loss of Ki67, such as SA--beta--gal (Fig. 1) .
Ans. We performed SA−βgal staining and immunoblotting (IB)/immunohistochemistry (IHC) for markers commonly used to detect senescent cells including CDK inhibitors (p16INK4a, p21CIP), p19ARF, and γH2AX (a marker for DNA--damage response, DDR), as this reviewer requested. These data are included in Fig E1 in our revised manuscript. d) The experiments in Fig. 2 (Fig. 3?) Ans. We agree with this comment, and removed "promotes intracellular cholesterol trafficking" from the sub--title of this section.
Referee #2 (Remarks):
The presented work explores so far understudied area of cancer research and potentially opens a new and interesting way of understanding the problem for tumor development and interaction between tumor and microenvironment, which may also have an impact on the development new treatment strategies. The suggested model seems to be adequate, however the follow up study would be necessary to understand, whether this phenomenon also takes place for further cell and cancer types. Technically, this very interesting and potentially powerful study, however, suffers from inadequate figure structure and low quality figure captions as well as extremely scarce explanations for the experiments/antibodies used etc. The text and figure captions have to be seriously edited, and adjusted to form a readable story, which is now cannot be published in this form. Besides, some data might need better verification. Please find below the selected questions/suggestions. The whole manuscript, however, has to be improved. Please note that the experiment for the figure 4 looks very strange and has to be at least repeated and the results displayed in the different way. Ans. We now explain in the legend the reason for the inclusion of the lung section of AdCre--induced tumours, as requested. Fig 1B. Ans. For %Ki67 quantification in the tumours, we analysed lung sections from total 20 BVE mice at ages from 18 to 100 days, and a total of 3613 - 37505 tumour cells per each mouse (average 16423 tumour cells/mouse) were evaluated for Ki67 positivity. As this reviewer suggested, we categorized these animals into 4 groups (<4wk, 4--6wk, 6--8wk, >8wk, n=4 to 6 for each group) and presented %Ki67 as an average +/--SD of each group in the graph. Based on this quantitative analysis, we prepared new IHC images representative for the averaged %Ki67 in each group. Unfortunately, we found technical difficulties to quantify %Ki67 in the wt lung AT2 cells (normal counterpart of tumour cells) because of the rarity of AT2 cells in wt lungs and difficulty to identify AT2 cells on the wt sections counterstained with hematoxylin only. The aim of this analysis is to quantitatively confirm the dynamic reduction of Ki67 positivity in tumours during the time course, and we believe %Ki67 data in tumours are sufficient for this purpose. Fig. 1C . The data display will be significantly enhanced when the Mac2 staining will be demonstrated on the section adjacent to the HE one, also showing both magnifications, which were used for the HE. In this way the morphological characteristics of the cells mentioned in the manuscript text can be compared to and supported by the Mac 2 staining. Ans. We prepared H&E and Mac2 IHC using serial sections, and imaged at x100 and x400 magnifications (see new Fig 1D) . Figure S1 . Fig. 1A . A sentence explaining the purpose of the cell isolation would significantly add to the readability. Ans. We revised the legend to describe the purpose to develop this method.
Fig. S1B. It makes more sense to display similar magnification (--s) of the phase--contrast micrographs for the different cell isolates. When it is not quite representative, it might be helpful to include 2 magnifications for each cell type.
Ans. We prepared images at the same magnifications (x200) (see new Fig. E2B) .
Fig. S1C. Why the Fr--2 cells were displayed? There is also no explanation in the text of the manuscript as I could found. Please provide brief description and reference for the Papanicolau stain, and what this stain is for. Fig. S1D. Why was SP--C staining included? What does it show?
Ans. We initially named 3 populations fractionated from BVE lung as Ans. We revised the figure legend as requested, with concisely describing the purpose of each panel.
Fig. 2D. Would be really helpful to display the same cells for phase--contrast and giemsa stain, which is I hope not restrictively hard to achieve, but significantly enhance the convincing power of the images. Please also indicate, "phase--contrast" as you indicated giemsa on appropriate images to perform a uniform and easy readable figure.
Ans. We prepared a phase--contrast image and a Giemsa image using IMC culture for 2 weeks, with indicating "phase--contrast" and ""Giemsa" as this reviewer requested (see new Fig. 2D) . 
Please display the micrographs with the same magnification so that the cell morphology can be directly compared to support the claims in the manuscript text.
Ans. These photos (Fig 3A, left and middle) are at the same magnification as indicated with scale bars. In standard cultures, CMT64 cells develop typical epithelial clusters, in which the cells are tightly packed. In contrast, in the presence of IMC--CM, CMT64 cells showed a more disperse distribution, some of which lost cell--to--cell contacts. These cells showed a more spread morphology, showing relatively larger cell sizes when examined by a phase--contrast microscope. This is also the case in confocal images in Fig 3D for Fig 3B, too) . Ans. We again apologize these mistakes. We revised the legends for Fig 3A/ Ans. An image of CMT64 cells in standard culture (DMEM + 10%FCS) is displayed as a control. We described this in the figure legend.
Please indicate the graphs and photos in the figure caption (as for

Figs 3C and D need serious re--phrasing and description of the images step by step.
Immunofluorescence images lack scale bars. Ans. We added scale bars in confocal images in Fig. 3D . Was Gapdh used as a control on the Fig. 3C ? Ans. Yes, we described the purpose of Gapdh RT--PCR as a control in the figure legend. Fig 3D? Ans. Yes, primary AT2 cells cultured in standard media (DMEM + 10%FCS) labelled as "AT2 w/o IMC--CM" serve as a control to show the effects of IMC--CM added in the AT2 culture (shown in the right, labelled as "AT2 with IMC--CM"). We described this in the figure legend. Images on the Fig. 3C (3D? ) immunofluorescence were possibly taken at different magnifications.
Was any control displayed on the
Ans. Two images in the left were both taken with 60x objective, and processed using Image J and Huygens deconvolution software in an entirely identical way. Possible reasons for the cell size difference between them are described above. The right image was 3x enlarged (3x zoom) using the zoom function equipped in FV1000 confocal acquisition software when this image was taken, but not cropped after image acquisition. This image highlights a dividing vimentin+ cell (in cytokinesis) with internalized E--cadhein, as explained in our text.
These should be indicated and marked on the figure captions. Besides, for these figures the reader does not need material and method details in the figure captions. Please adjust.
Ans. We revised the legend in Fig 3 as above. Ans. We moved this figure to supplementary Fig E5 in our revised manuscript (see below) . Aims of these experiments were described in the expanded view section. We initially included this figure to confirm that IMCs secrete substantial amounts of PDGFA/TGFb/CCL6. Given the highly sensitive nature of mass--spec detection of peptides, we believe that confirming secreted proteins by other methods (e.g. immunoblotting) is still useful. Fig E4) from tumour--bearing lungs to compare secreted protein levels between IMCs and lung fibroblasts as this reviewer requested. To avoid any confusion, we collected conditioned media in serum--free culture conditions for CCL6 and TGFβ detection. Our preliminary analyses confirm that CCL7 is secreted mainly by lung fibroblasts but its secretion levels by IMCs are relatively low. Therefore, CCL7 immunoblotting was excluded from the figure. Unfortunately, PDGFA was undetectable in serum--free conditioned media of IMCs, which could be due to the possible requirement of serum factors to induce PDGFA expression, and/or to stabilize secreted PDGFA. So the PDGFA blot remains in the form we initially submitted. We partially agree with this reviewer's suggestion to completely exclude this figure, but also find some merits as described above. So we decided to move this figure to the expanded view section (new Fig E5)   Figure 5 . Fig.  5A . Why co--stained with different antibodies? Needs explanation, which is present neither in the text, nor in the caption. Ans. The purpose of dual staining is to unambiguously confirm Mac2+ IMCs and Ecad+ AT2 cells. Also, since Mac2 and Ecad are cell surface (plasma membrane) proteins, dual staining confirms CCR1 localization at the plasma membrane. CCR1 must be at the plasma membrane to function as a cell surface receptor, so it is useful to show its membrane localization. We can find substantial amounts of intracellular CCR1 in IMCs, consistent with a previous publication describing that CCR1 is not efficiently recycled when internalized (Elsner et al, Allergy 60: 1386--1393). We described these in our revised manuscript text and figure legends. Referee #3 (Remarks): EMM--2014--04838 comments The study of Kamata et al addresses interesting and relevant topics on the mechanism of activation of macrophage related cell in tumor microenvironment. The study contains several novel observations, including the response of macrophages--like to the cholesterol--binding protein NPC2. However the study contains several experimental deficiencies, especially in the data dealing with intracellular trafficking mechanisms induced by NPC2.
In the revised version we established lung fibroblasts (new
Major comments 1. Figure 8 B. The signal for LAMP2 staining for lysosomes is too strong , the image is overexposed. The lysosomes, if stained properly, represent very clear discrete structures. The Filipin staining is also overexposed. Therefore the overlap in two signals can be an artefact, and least in part, as well as the quantification of such images. Images with better resolution and improved image acquisition have to be provided. It is also recommended to use not only LAMP2, that is frequently conserved as maker for late endosomes, by also LAMP1. Moreover, markers for other intracellular structures have to be used in parallel to prove the specify of co--localization (EEA1, TGN, Golgi)
Ans. As shown in revised Fig 7A/C (previous Fig 8A/C) , extremely high filipin staining (categorized as 3+ in our quantitative analysis) was observed in 10--15% of Npc2 hypo/+ IMCs, but rarely in Npc2 +/+ IMCs. As this reviewer claims, filipin staining in these Npc2 hypo/+ IMCs containing very high levels of free cholesterol seems to be overexposed, but this level of exposure was also needed to distinguish weak vesicular filipin staining (categorized as 1+ in our quantitative assay) from negative vesicular staining (categorized as 0). We set the exposure condition using Npc2 +/+ IMCs, and the same condition was applied to Npc2 hypo/+ IMCs. When we set the exposure conditions to those used for Npc2 hypo/+ IMCs to avoid overexposure, image resolution was not sufficient for accurately categorizing low level staining, resulting in inaccurate quantification. Therefore, we believe that our imaging condition is optimal for quantitative analyses, even though some Npc2 hypo/+ IMCs show extremely high filipin staining with saturated fluorescence intensities. However, we agree with this reviewer's criticism for LAMP2/filipin dual staining of Npc2 hypo/+ IMCs (in previous Fig  8B,  revised  Fig  7B) , especially for LAMP2 immunofluorescence. The aim of this panel was to show if filipin staining (free cholesterol) could be associated with LAMP2+ vesicles, but not to perform quantitative comparisons. To accurately determine LAMP2+ structures, exposure levels must be controlled. We therefore revised LAMP2/filipin staining using confocal imaging with appropriately adjusting exposure conditions to avoid fluorescence signal saturation, and also filipin--stained IMCs were co--stained for LAMP1, EEA1, TGN46 and Giantin. Through these experiments, we obtained some new findings that are now incorporated in Fig 7B, E10 & E11 . These findings are summarized as following:
(1) Coarse structures strongly stained with filipin are included in LAMP2+ large vesicles (revised Fig 7B) that are mostly devoid of LAMP1/EEA1/TGN46/Giantin staining (Fig E10) , suggesting that free cholesterol does not accumulate at LAMP1+ late endosomes/lysosomes or other cellular organelles in Npc2 hypo/+ IMCs.
(2) These coarse structures are observed near ventral surfaces of the IMCs contacting with extracellular substrata, distinct from the main LAMP2 distribution at the dorsal side ( Fig  E11A) . (3) The filipin--positive structures are partially associated with vertical F--actin staining suggestive of podosomes (Fig E11B) .
Based on these observations, we conclude that LAMP2 is not a specific marker for LE/Ly in IMCs, and LAMP1 is more suitable for imaging studies for CCL6 localization at vesicular lysosomes as this reviewer suggested (see below).
2. Figure  8C . Fig 5H) , and did not reach statistically significant levels. Thus, transcriptional up--regulation is unlikely to be the major cause for the intracellular NPC2 accumulation in IMCs treated with exogenous NPC2.
To unambiguously confirm NPC2 uptake by IMCs, we treated freshly isolated IMCs with 82.5nM recombinant NPC2 protein conjugated with Alexa488 (Huang et al, PLoS One 9: e88893) for 2h, followed by 2h chase in NPC2--free media. Robust uptake of NPC2--Alexa488 was confirmed by live confocal imaging (revised Fig 5G) . Interestingly, NPC2--Alexa 488 incorporated by IMCs showed not only lysosome--like fine vesicular distribution but also reticular structures surrounding coarse vesicular puncta observed in the DIC image (zoomed images in Fig  5G) . The latter distribution is reminiscent of LAMP2 staining shown in Fig 7B, suggesting that NPC2 uptaken by IMCs could be transferred from LE/Ly to the coarse vesicular structures associated with LAMP2.
Other points (not mentioned by reviewers)
(1) We found a mis--calculation of log--rank p--values for the survival data presented in Fig 6A (p--values not indicated in the figure, but described in the text). We corrected these in our revised manuscript (in the text). (2) We found inappropriate descriptions for our statistical analyses in the original submission (in Materials and Methods). We revised these statements in our revised manuscript ("Statistics" section in Material and Methods). Of note, we revised all t--tests using Welch's t--test, so those calculated by student's t--test in our previous figures were all corrected.
Reviewer-only Figure 1 , were cultured for 3hrs in serum-free, calcium-free DMEM with or without 50µg/ml bNPC2, immunostained for CCL6 and endo-lysosome markers (VAMP3/LAMP1/EEA1), and imaged by CLSM. Scale bars, 5µm. Calcium-free media was used to minimize CCL6 secretion (see below B), since secreted CCL6 could be endocytosed and delivered to endo-lysosomes, which potentially causes mis-interpretation of the data. In the absence of exogenous NPC2 (-bNPC2, left panels), fine vesicular or reticular CCL6 staining partially colocalized with VAMP3 (recycling endosome marker), indicating that CCL6 is delivered from the Golgi to the periphery through recycling endosomes in the absence of bNPC2. In contrast, in the presence of bNPC2 (+bNPC2, right panels), CCL6 staining was detected as relatively larger vesicles not costained with VAMP3, LAMP1 or EEA1.
B. Immunoblot analysis of CCL6 secretion by IMCs cultured in calcium-free media for 24h. In calciumfree media, CCL6 secretion into CM was clearly decreased, whereas intracellular CCL6 protein levels were increased. Thank you for the submission of your revised manuscript to EMBO Molecular Medicine. We have now received the enclosed reports from the referees that were asked to re-assess it. As you will see the reviewers are now globally supportive, albeit with a few remaining minor issues and I am pleased to inform you that we will be able to accept your manuscript pending the following final amendments:
1) I invite you to adhere to Reviewer 1's requests to tone-down your conclusions and to clarify the sentence mentioned. Please also deal with Reviewer 2's requests to improve presentation of Figure  2 . These and the following amendments will be dealt with editorially.
2) On a related note, I would also ask you to make sure the frames indicating magnified insets are precisely positioned and sized to reflect the actual magnifications (see Fig. 6F ).
3) Please provide all figures as separate files and the manuscript as a Word file.
4) Could you please state the gender of the mice used in the experiments? Please also mention their age in the Materials and Methods section (the latter in addition to the figure legends, which you have already done).
5)
We are now encouraging the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or at least the key gels used in the manuscript? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation may be useful but is not essential. The PDF files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this just contact me.
6) Every published paper now includes a 'Synopsis' to further enhance discoverability. Synopses are displayed on the journal webpage and are freely accessible to all readers. They include a short standfirst as well as 2-5 one sentence bullet points that summarise the paper. Please provide the synopsis including the short list of bullet points that summarise the key NEW findings. The bullet points should be designed to be complementary to the abstract -i.e. not repeat the same text. We encourage inclusion of key acronyms and quantitative information. Please use the passive voice. Please attach this information in a separate file or send them by email, we will incorporate it accordingly. You are also welcome to suggest a striking image or visual abstract to illustrate your article. If you do please provide a jpeg file 550 px-wide x 400-px high.
Please submit your revised manuscript within two weeks.
I look forward to reading the final evised version of your manuscript as soon as possible.
***** Reviewer's comments ***** Referee #1 (Comments on Novelty/Model System):
The mouse model recapitulates a tumor initiating tumor mutation discovered in a subset of human lung cancers and the pathological features. Thus it is relevant.
Referee #1 (Remarks):
In this revised manuscript, the authors try to respond thoroughly to the comments from me and the others. (The other reviewers were very thoughtful and constructive.)
The manuscript has been significantly improved with additional data and better description.
However, the authors could tone down their specific conclusions and rather speculate them broadly (considering alternative explanations). Although I am not completely persuaded by the authors argument, their findings may be published to be discussed/debated by a broader audience.
Upon editorial revision, I would like to see that the authors better define 'maintenance of early stagetumors'. Do they mean survival or prevent progression?
Referee #2 (Comments on Novelty/Model System):
The presented work deals with interesting and high impact area of cancer research and potentially opens a new way of understanding tumor development and tumor -microenvironment interaction, which may affect development of new treatment strategies. The suggested model seems to be adequate. In the revised article, the authors made a good job answering to the comments and suggestions, which, hopefully would significantly enhance the data robustness and persuasiveness of the manuscript.
Referee #2 (Remarks):
There are two minor comments concerning Figure 2 of the manuscript Figure 2D : The phase-contrast and Giemsa-stained images were indeed marked as requested. However, they do have different magnification (which is to be understood from different scale bars), and therefore itis difficult to see, whether they belong to the same sample or not. This discrepancy was not mentioned or explained. Many thanks for the email regarding acceptance of our manuscript in your pending final amendments.
We have addressed the six points you raised in your email as follows: Point 1.
a) I invite you to adhere to Reviewer 1's requests to tone-down your conclusions and to clarify the sentence mentioned.
In the revised manuscript we have altered the beginning of paragraph 3 in the Discussion to address the concerns of Reviewer 1 with regard to the role of IMCs.
Reviewer 1 would also like a better definition of "maintenance of early stage tumours", asking whether this means survival or progression. This refers to the situation in which we have treated BVE mice with a CCR1 inhibitor (Figure 4 ) and find that there is a substantial reduction in IMC and AT2 cell numbers following inhibitor treatment for 4 weeks. Since we know that CCR1 is predominantly expressed on IMCs and not AT2 cells, our suggestion is that the inhibitor targets IMCs and this has the secondary effect of reducing AT2 cell number. Thus, we conclude that IMCs are required for tumour maintenance. We prefer to use the term "maintenance" rather than "survival" or "progression" for the following reasons: The term "progression" is not relevant in this context since we are not assessing the further development of tumours. The term "survival" is also not accurate because we cannot distinguish between alterations in survival of the tumour cells (due to apoptosis/necrosis) and immune surveillance. In all, we think the term maintenance is most appropriate. We hope you agree.
b) Please also deal with Reviewer 2's requests to improve presentation of Figure 2.
Regarding Fig 2D, we think there was some misunderstanding, causing some. For this panel, IMCs were cultured on tissue culture plates for 2 weeks, and phase-contrast images were taken with 40x objective. Then the cells were trypsinised and smeared on glass slides for Giemsa staining. The image for Giemsa-stained cells was taken with 100x oil-immersion objective. Therefore, we cannot take phase-contrast and Giemsa images at the entirely same condition.
Since the Giemsa-stained cells were prepared by trypsinisation, their morphology was not identical to that in the phase-contrast image of the cells in culture. Microscopic observation using 100x oil-immersion objective is a standard method to investigate detailed morphological characteristics of Giemsa-stained hematopoietic cells, and we do not think it is reasonable to use lower magnification (same as phase-contrast imaging) for imaging of the Giemsa-stained cells. We added some descriptions in Fig 2D legend to explain our methodology for these images. I would also ask you to make sure the frames indicating magnified insets are precisely positioned and sized to reflect the actual magnifications (see Fig. 6F ).
Thank you for realising this -this has now been adjusted.
Point 3
Please provide all figures as separate files and the manuscript as a Word file.
This is done Point 4
Could you please state the gender of the mice used in the experiments? Please also mention their age in the Materials and Methods section.
